TP53 and acute myeloid leukemia: Moreover, a previous report demonstrated that the WEE1 inhibitor AZD1775 combined with HDAC inhibitors targeted human acute myeloid leukemia cells harboring various genetic mutations, including p53-wild type, p53-deficient, and FLT3-ITD leukemia cells [9].